Haisco Secures NMPA Approval for First‑In‑Class Oral Complement Inhibitor, Boosting Revenue & Innovation
Haisco’s new oral complement inhibitor, Ciprocopan Succinate, gains NMPA approval – boosting China’s first‑in‑class drug pipeline and driving 2026 earnings growth.
2 minutes to read